<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9689">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05692492</url>
  </required_header>
  <id_info>
    <org_study_id>ZSP1601-22-03</org_study_id>
    <nct_id>NCT05692492</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 2b Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Raynovent Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Raynovent Biotech Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the efficacy and the safety of two doses of&#xD;
      ZSP1601 for 48 weeks versus placebo in adult NASH patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2023</start_date>
  <completion_date type="Anticipated">December 16, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 16, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients with improvement of steatohepatitis and no worsening of liver fibrosis or improvement in liver fibrosis greater than or equal to one stage and no worsening of the steatohepatitis</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percent of patients with improvement of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis on NASH-CRN Fibrosis Score or improvement in liver fibrosis greater than or equal to one stage and no worsening of the steatohepatitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with resolution of steatohepatitis and no worsening of fibrosis or improvement of fibrosis by at least 1 stage and no worsening of steatohepatitis</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with steatohepatitis improvement and improvement of fibrosis by at least 1 stage</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with steatohepatitis resolution and improvement of fibrosis by at least 1 stage</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with steatohepatitis resolution and no worsening of fibrosis</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with steatohepatitis improvement and no worsening of fibrosis</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver fat content (LFC) as measured by MRI-PDFF</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver chemistry（ALT,AST,GGT）</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>ZSP1601 50mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601</intervention_name>
    <description>50mg BID</description>
    <arm_group_label>ZSP1601 50mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601</intervention_name>
    <description>100mg BID</description>
    <arm_group_label>ZSP1601 100 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. NASH histological diagnosis on a liver biopsy performed ≤ 24 weeks before&#xD;
             randomization, and NAS≥4 (at least 1 point each in inflammation and ballooning), and&#xD;
             fibrosis score F2 or F3, and no other chronic liver disease&#xD;
&#xD;
          2. Subjects having given her/his written informed consent&#xD;
&#xD;
          3. Good compliance with the protocol and agree to have liver biopsy performed&#xD;
&#xD;
          4. Subjects (including their partners) agreed to use effective contraception throughout&#xD;
             the study period and up to 24 weeks after discontinuation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cirrhosis or liver biopsy suggestive of cirrhosis&#xD;
&#xD;
          2. Metabolic surgery or new technology treatment for weight loss within 5 years prior to&#xD;
             randomization or planned during the study period&#xD;
&#xD;
          3. Type 1 diabetes&#xD;
&#xD;
          4. HIV infection&#xD;
&#xD;
          5. Patients with severe or uncontrollable underlying diseases, unsuitable for treatment&#xD;
             with ZSP1601, unable to complete study follow-up, or likely to affect the evaluation&#xD;
             of trial results judged by investigator&#xD;
&#xD;
          6. Previous malignancy within 5 years&#xD;
&#xD;
          7. Treatment with hepatoprotective drugs&#xD;
&#xD;
          8. Excessive alcohol consumption for 12 or more consecutive weeks within 1 year prior to&#xD;
             screening&#xD;
&#xD;
          9. Pregnant and lactating women or those with a positive serum pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinlin Hou</last_name>
    <phone>02061641888</phone>
    <email>jlhousmu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NanFang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinlin Hou</last_name>
      <phone>020-61641888</phone>
      <email>jlhousmu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>December 25, 2022</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>June 6, 2023</last_update_submitted>
  <last_update_submitted_qc>June 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

